Date(s) - September 24,2021 - September 26,2021
8:00 am - 1:00 pm
Paris Las Vegas
HOTEL INFO: please call us to assist with room reservation
Paris Las Vegas
group rate $119 Thursday &nFriday night, $209 Saturday night single or double occupancy
Friday September 24, 2021
Gregory Holmquist, Pharm.D., BCOP
Pain and Palliative Care Specialist
Dr. Holmquist is on the Board of Advisors of the American Society of Pain Educators. Over the past decade, he has been invited to present over 1,000 CME and CE lectures on pain management across the country. He shares practical and relevant clinical information, with a touch of humor, ensuring that audiences not only listen but also hear an important message on managing pain and making a difference in the lives of their patients.
PILLS, PEOPLE, & PAIN: UNDERSTANDING THE PROBLEM-FINDING THE SOLUTION
ACPE # 0043-9999-20-013-L08-P
1. State three myths and barriers to providing effective use of pharmacological therapies for pain control in patients.
2. State five features of patients that differentiate patients with acute versus chronic pain syndromes.
3. Differentiate addiction, dependence, tolerance, pseudoaddiction, pseudotolerance, and hyperalgesia.
4. Recommend and effectively utilize standard and innovative pharmacological strategies to effectively palliate uncontrolled pain.
5. State the role of selected co-analgesic and adjuvant pain therapies (e.g. antidepressants, anticonvulsants, NSAIDs, topical approaches) in the management of pain.
6. Compare and contrast the pharmacology, pharmacokinetics, side effects and clinical utilization of the commercially available opioid products.
7. Recognize the patient / chronic pain syndrome which can receive the greatest potential benefit from a trial of opioid therapy and be able to implement this therapeutic approach in a manner that minimize the risks of drug diversion, addiction, and side effects.
8. State the common side effects associated with pain medications and be able to recommend strategies to prevent the side effects from impacting the patients’s quality of life.
Saturday September 25, 2021
James Lewis, Pharm.D., FIDSA
University of Texas at San Antonio
Dr. James Lewis received his BPharm and Pharm.D. degrees from Washington State University and completed his PGY-2 infectious diseases residency at the University of Texas Health Sciences Center in San Antonio. Dr. Lewis currently serves as the infectious diseases pharmacy specialist and co-director of the antibiotic stewardship program at University Health System in San Antonio where is also an adjunct associate professor in the division of infectious diseases at the UT health sciences center. Dr. Lewis’ has published many abstracts at international meetings as well as peer reviewed papers in the areas of antifungal and antibacterial resistance as well as antibiotic stewardship. In addition he is a member of the editorial board of Clinical Microbiology Reviews and serves a serves as a reviewer for several other journals. In 2011 he was named a fellow of the infectious diseases society of America.
INVASIVE FUNGAL INFECTIONS AND THEIR TREATMENT
ACPE # 0043-9999-20-004-L01-P
1. Describe the strengths and weaknesses of three widely used classes of systemic antifungal agents.
2. List the most common pathogens in invasive fungal infections and their usual antifungal susceptibility profiles.
3. Identify areas where further research is needed in the treatment of invasive fungal infections.
Sunday September 26, 2021
Dr. Reginal Harris, Pharm D, JD
Reginal Harris is the founder and president of Infosource Communications, a pharmacy consulting and professional speaking company, which offers continuous quality improvement programs, resource management consulting, mock Joint Commission accreditation surveys, and leadership mentoring and other clinical services. He has served on the college of pharmacy faculty for Texas A&M University Health Sciences Center and the University of Colorado Health Sciences Center. He is the author of Patient’s FIRST: A Case Study on How the Collaborative Approach to Patient Care Has Improved Overall Safety and Treatment Outcomes.
PHARMACY LAW: PREVENTING REGULATORY VIOLATIONS WHEN DISPENSING CONTROLLED SUBSTANCES
- Define common terms relating to pathology of opioid misuse and addiction and what steps pharmacists can take when dispensing and counseling at-risk patients taking a controlled substance.
- Describe how a state’s Prescription Drug Monitoring Program assists pharmacists when determining the validity, use, misuse, and abuse of controlled substances.
- Describe how recent changes in the Controlled Substances Act help pharmacists identify “red flags” when receiving and evaluating controlled substance prescriptions.
- Define the concept of Risk Evaluation & Mitigation Strategy (REMS) as an evidence-based approach of assessing patients with chronic pain who are initiated on opioid or other pain medications and how to calculate the morphine milligram equivalents.
- Apply standardized scales and tools to document pain characteristics and to guide medication management decisions by comparing/contrasting “strengths v. weaknesses” and “specificity v. sensitivity” of the scales and tools.
- Explain the FDA evaluation blueprint as a tool to identify patients showing signs of addiction, abuse, misuse, or overuse of pain medications.
- Apply the REMS and/or FDA approach to develop a comprehensive, customized treatment plan for a patient initiated on an opioid analgesic or other pain medications.
- Document treatment recommendations using the S.O.A.P. format to reinforce patient-clinician responsibilities.
Don't have a Paypal account?
You do not need a Paypal Account to pay with Paypal. Paypal allows you to pay online simply by entering your credit card and billing information.